Overview

Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)

Status:
Completed

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

High-dose cytarabine (HiDAC) is considered a standard chemotherapy treatment for patients with acute myeloid leukemia. However, most patients receiving this therapy are required to be admitted to the hospital during their treatment course. The purpose of this study is to compare the safety and cost of high-dose cytarabine treatment given in an in-patient setting versus an out-patient setting.

Phase:

N/A

Details

Lead Sponsor:

University of Rochester

Treatments:

Cytarabine